HDAC9 and primary cutaneous T-cell non-Hodgkin lymphoma: Vorinostat is approved for the treatment of cutaneous T-cell lymphoma, and is a member of the hydoxamic acid class of histone deacetylase inhibitors (HDACi), which inhibit the class I and II HDAC family of transcriptional co-repressors [34,35].